Dose Finding Phase 1 Study of the Treatment of Metastatic Melanoma With MPC-6827 in Combination With Temozolomide

Inclusion Criteria:

- Histologically proven melanoma

- For subjects with brain metastases that require radiation, therapy must have been
completed at least 4 weeks prior to Day 1 of Study Drug

- Have unresectable melanoma with measurable metastases

- Be a minimum of 4 weeks since prior surgical resection or major surgical procedure
and a minimum of 2 weeks since chemotherapy/ biochemotherapy

- Performance score of Karnofsky ≥ 60%, or Eastern Cooperative Oncology Group (ECOG) ≤
2, or WHO ≤ 2

- If steroids are needed, be on a stable or decreasing dose of steroids for at least 1
week

Exclusion Criteria:

- Hypersensitivity to Cremophor EL

- Have current/active intratumor hemorrhage by CT/MRI within 3 weeks prior to Day 1 of
Study Drug confirmed by CT/MRI

- Have ocular melanoma

- Have primary intradural melanoma or leptomeningeal involvement

- Have cardiovascular disease (unstable angina or MI)

- Have cerebrovascular disease (stroke and/or TIA)

- Have uncontrolled hypertension

- Have a cardiac ejection fraction < 50%

- Have Troponin-I elevated above the normal range